Form 4: Prime Medicine CFO Receives 800k Stock Option Grant
Statement of Changes in Beneficial Ownership
Prime Medicine CFO Svetlana Makhni was granted 800,000 stock options with a strike price of $3.67, vesting over four years.
Summary
- Svetlana Makhni, Chief Financial Officer of Prime Medicine, Inc., was granted 800,000 stock options on April 16, 2026.
- The options have an exercise price of $3.67 per share.
- The options are set to expire on April 16, 2036.
- Vesting schedule: 25% of the shares vest on April 16, 2027, with the remaining 75% vesting in equal monthly installments over the subsequent 36 months.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral administrative filing regarding standard executive compensation, which does not signal a change in company fundamentals.
Positives
- Alignment of executive interests with long-term shareholder value through equity-based compensation.
- Retention mechanism for key leadership personnel via a four-year vesting schedule.
Negatives
- Potential for future shareholder dilution upon the exercise of these options.
Risks
- Market volatility affecting the value of the granted options.
- Dependence on continued service for the full vesting of the equity grant.
Future Outlook
The grant is subject to the reporting person's continued service, indicating a long-term commitment to the company's operational goals.
Management Comments
- The filing does not contain narrative management commentary.
Industry Context
StockSavvy.ai notes that equity grants for C-suite executives in the biotechnology sector are standard practice to incentivize long-term R&D and commercialization milestones.
Comparison to Industry Standards
- The four-year vesting schedule is consistent with standard corporate governance practices for executive equity compensation in the U.S. biotech industry.
- The grant size is typical for a CFO role in a clinical-stage biotechnology company.
Legal Proceedings
- None mentioned.
Related Party Transactions
- None mentioned.
Stakeholder Impact
- Shareholders may experience minor dilution if these options are exercised in the future.
Next Steps
- Vesting of the first tranche of options on April 16, 2027.
Key Dates
| Date | Description |
|---|---|
| 04/16/2026 | Date of the stock option grant transaction. |
| 04/17/2026 | Date the Form 4 was signed and filed. |
| 04/16/2027 | Initial vesting date for 25% of the granted options. |
| 04/16/2036 | Expiration date of the stock options. |
Keywords
Prime Medicine, PRME, Form 4, Insider Trading, Stock Options, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.